2026-07-21T14:15:11Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/110882025-03-26T11:51:18Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19609

00925njm 22002777a 4500 dc Donnelly, J Peter author Chen, Sharon C author Kauffman, Carol A author Steinbach, William J author Baddley, John W author Verweij, Paul E author Clancy, Cornelius J author Wingard, John R author Lockhart, Shawn R author Groll, Andreas H author Sorrell, Tania C author Bassetti, Matteo author Akan, Hamdi author Alexander, Barbara D author Andes, David author Azoulay, Elie author Bialek, Ralf author Bradsher, Robert W author Bretagne, Stéphane author Calandra, Thierry author Caliendo, Angela M author Castagnola, Elio author Cruciani, Mario author Cuenca-Estrella, Manuel author Decker, Catherine F author Desai, Sujal R author Fisher, Brian author Harrison, Thomas author Heussel, Claus Peter author Jensen, Henrik E author Kibbler, Christopher C author Kontoyiannis, Dimitrios P author Kullberg, Bart-Jan author Lagrou, Katrien author Lamoth, Frédéric author Lehrnbecher, Thomas author Loeffler, Jurgen author Lortholary, Olivier author Maertens, Johan author Marchetti, Oscar author Marr, Kieren A author Masur, Henry author Meis, Jacques F author Morrisey, C Orla author Nucci, Marcio author Ostrosky-Zeichner, Luis author Pagano, Livio author Patterson, Thomas F author Perfect, John R author Racil, Zdenek author Roilides, Emmanuel author Ruhnke, Marcus author Prokop, Cornelia Schaefer author Shoham, Shmuel author Slavin, Monica A author Stevens, David A author Thompson, George R author Vazquez, Jose A author Viscoli, Claudio author Walsh, Thomas J author Wheat, L Joseph author Warris, Adilia author White, P Lewis author Zaoutis, Theoklis E author Pappas, Peter G author 2020-09-12 Background: Invasive fungal diseases (IFDs) remain important causes of morbidity and mortality. The consensus definitions of the Infectious Diseases Group of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group have been of immense value to researchers who conduct clinical trials of antifungals, assess diagnostic tests, and undertake epidemiologic studies. However, their utility has not extended beyond patients with cancer or recipients of stem cell or solid organ transplants. With newer diagnostic techniques available, it was clear that an update of these definitions was essential. Methods: To achieve this, 10 working groups looked closely at imaging, laboratory diagnosis, and special populations at risk of IFD. A final version of the manuscript was agreed upon after the groups' findings were presented at a scientific symposium and after a 3-month period for public comment. There were several rounds of discussion before a final version of the manuscript was approved. Results: There is no change in the classifications of "proven," "probable," and "possible" IFD, although the definition of "probable" has been expanded and the scope of the category "possible" has been diminished. The category of proven IFD can apply to any patient, regardless of whether the patient is immunocompromised. The probable and possible categories are proposed for immunocompromised patients only, except for endemic mycoses. Conclusions: These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk. Clin Infect Dis. 2020 Sep 12;71(6):1367-1376. 10.1093/cid/ciz1008 1537-6591 Clinical infectious diseases 31802125 http://hdl.handle.net/20.500.12105/11088 Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.